Mathurin Fumery1, Siddharth Singh2, Parambir S Dulai3, Corinne Gower-Rousseau4, Laurent Peyrin-Biroulet5, William J Sandborn3. 1. Division of Gastroenterology, University of California San Diego, La Jolla, California; Gastroenterology Unit, Epimad Registry, Amiens University Hospital, Amiens, France. Electronic address: mathurinfumery@gmail.com. 2. Division of Gastroenterology, University of California San Diego, La Jolla, California; Division of Biomedical Informatics, University of California San Diego, La Jolla, California. 3. Division of Gastroenterology, University of California San Diego, La Jolla, California. 4. LIRIC Inserm, Unit 995, Lille University, Lille, France; Epidemiology Unit, Epimad Registry, Lille University Hospital, France. 5. Gastroenterology Unit, Inserm U954, Nancy University and Hospital, Nancy, France.
Abstract
BACKGROUND & AIMS: A comprehensive knowledge of the natural history of ulcerative colitis (UC) helps understand disease evolution, identify poor prognostic markers and impact of treatment strategies, and facilitates shared decision-making. We systematically reviewed the natural history of UC in adult population-based cohort studies with long-term follow-up. METHODS: Through a systematic literature review of MEDLINE through March 31, 2016, we identified 60 studies performed in 17 population-based inception cohorts reporting the long-term course and outcomes of adult-onset UC (n = 15,316 UC patients). RESULTS: Left-sided colitis is the most frequent location, and disease extension is observed in 10%-30% of patients. Majority of patients have a mild-moderate course, which is most active at diagnosis and then in varying periods of remission or mild activity; about 10%-15% of patients experience an aggressive course, and the cumulative risk of relapse is 70%-80% at 10 years. Almost 50% of patients require UC-related hospitalization, and 5-year risk of re-hospitalization is ∼50%. The 5-year and 10-year cumulative risk of colectomy is 10%-15%; achieving mucosal healing is associated with lower risk of colectomy. About 50% of patients receive corticosteroids, although this proportion has decreased over time, with a corresponding increase in the use of immunomodulators (20%) and anti-tumor necrosis factor (5%-10%). Although UC is not associated with an increased risk of mortality, it is associated with high morbidity and work disability, comparable to Crohn's disease. CONCLUSIONS: UC is a disabling condition over time. Prospective cohorts are needed to evaluate the impact of recent strategies of early use of disease-modifying therapies and treat-to-target approach with immunomodulators and biologics. Long-term studies from low-incidence areas are also needed.
BACKGROUND & AIMS: A comprehensive knowledge of the natural history of ulcerative colitis (UC) helps understand disease evolution, identify poor prognostic markers and impact of treatment strategies, and facilitates shared decision-making. We systematically reviewed the natural history of UC in adult population-based cohort studies with long-term follow-up. METHODS: Through a systematic literature review of MEDLINE through March 31, 2016, we identified 60 studies performed in 17 population-based inception cohorts reporting the long-term course and outcomes of adult-onset UC (n = 15,316 UC patients). RESULTS: Left-sided colitis is the most frequent location, and disease extension is observed in 10%-30% of patients. Majority of patients have a mild-moderate course, which is most active at diagnosis and then in varying periods of remission or mild activity; about 10%-15% of patients experience an aggressive course, and the cumulative risk of relapse is 70%-80% at 10 years. Almost 50% of patients require UC-related hospitalization, and 5-year risk of re-hospitalization is ∼50%. The 5-year and 10-year cumulative risk of colectomy is 10%-15%; achieving mucosal healing is associated with lower risk of colectomy. About 50% of patients receive corticosteroids, although this proportion has decreased over time, with a corresponding increase in the use of immunomodulators (20%) and anti-tumor necrosis factor (5%-10%). Although UC is not associated with an increased risk of mortality, it is associated with high morbidity and work disability, comparable to Crohn's disease. CONCLUSIONS: UC is a disabling condition over time. Prospective cohorts are needed to evaluate the impact of recent strategies of early use of disease-modifying therapies and treat-to-target approach with immunomodulators and biologics. Long-term studies from low-incidence areas are also needed.
Authors: K H Katsanos; S Vermeire; D K Christodoulou; L Riis; F Wolters; S Odes; J Freitas; Ole Hoie; Marina Beltrami; G Fornaciari; J Clofent; P Bodini; M Vatn; Paula Borralho Nunes; B Moum; P Munkholm; C Limonard; R Stockbrugger; P Rutgeerts; E V Tsianos Journal: Digestion Date: 2007-06-26 Impact factor: 3.216
Authors: C Jakobsen; J Bartek; V Wewer; I Vind; P Munkholm; R Groen; A Paerregaard Journal: Aliment Pharmacol Ther Date: 2011-10-09 Impact factor: 8.171
Authors: Daniel Sjöberg; Tommy Holmström; Märit Larsson; Anne-Lie Nielsen; Lars Holmquist; Anders Ekbom; Anders Rönnblom Journal: J Crohns Colitis Date: 2013-09-12 Impact factor: 9.071
Authors: Marianne K Vester-Andersen; Michelle V Prosberg; Tine Jess; Mikael Andersson; Bo G Bengtsson; Thomas Blixt; Pia Munkholm; Flemming Bendtsen; Ida Vind Journal: Am J Gastroenterol Date: 2014-03-18 Impact factor: 10.864
Authors: Cynthia W Ko; Siddharth Singh; Joseph D Feuerstein; Corinna Falck-Ytter; Yngve Falck-Ytter; Raymond K Cross Journal: Gastroenterology Date: 2018-12-18 Impact factor: 22.682
Authors: Siddharth Singh; James A Proudfoot; Parambir S Dulai; Vipul Jairath; Mathurin Fumery; Ronghui Xu; Brian G Feagan; William J Sandborn Journal: Am J Gastroenterol Date: 2018-06-21 Impact factor: 10.864
Authors: Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne Journal: Gut Date: 2019-09-27 Impact factor: 23.059
Authors: Edward L Barnes; Yue Jiang; Michael D Kappelman; Millie D Long; Robert S Sandler; Alan C Kinlaw; Hans H Herfarth Journal: Inflamm Bowel Dis Date: 2020-07-17 Impact factor: 5.325